Skip to main content
SpringerLink
Log in

Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia

  • Original
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Lipid-lowering therapy is associated with reduced cardiovascular risk. The aim of the present study was to investigate whether lipid-lowering therapy might be associated with changes in the concentrations of metabolically important hormone concentrations. We performed a randomised cross-over open-label trial with atorvastatin (10 mg/day) and fenofibrate (200 mg/day), each for 6 weeks separated by a 6-week washout period in 13 patients (5 men, 8 women, age 60.0±6.8 years, body mass index 30.0±3.0 kg/m2) with type 2 diabetes mellitus and mixed hyperlipoproteinaemia. Plasma ghrelin (RIA, Phoenix Pharmaceuticals, Mountain View, CA, USA), adiponectin (ELISA, Biovendor, Heidelberg, Germany) as well as resistin (ELISA, Linco Research, St. Charles, MO, USA) concentrations were measured before and after atorvastatin as well as before and after fenofibrate. Ghrelin (462±84 pg/ml before vs. 464±102 pg/ml after atorvastatin, n.s.; 454±85 pg/ml before vs. 529±266 pg/ml after fenofibrate, n.s.), resistin (24.4±7.4 pg/ml before vs. 23.7±9.1 pg/ml after atorvastatin, n.s.; 23.4±8.2 pg/ml before vs. 19.9±5.5 pg/ml after fenofibrate, n.s.), adiponectin (10.89±5.33 pg/ml before vs. 12.41±5.75 pg/ml after atorvastatin, n.s.; 12.58±9.87 pg/ml before vs. 10.27±5.23 pg/ml after fenofibrate, n.s.) and insulin levels did not change significantly during lipid-lowering therapy. In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22

    Article  Google Scholar 

  2. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357–362

    PubMed  CAS  Google Scholar 

  3. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, Collins D; Veterans Affairs HDL Intervention Trial (VA-HIT) (2003) Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26:1513–1517

    Article  PubMed  CAS  Google Scholar 

  4. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S (2004) Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197–2202

    Article  PubMed  CAS  Google Scholar 

  5. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C (2004) Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12:962–971

    Article  PubMed  CAS  Google Scholar 

  6. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228

    Article  PubMed  CAS  Google Scholar 

  7. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737

    Article  PubMed  CAS  Google Scholar 

  8. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA (2001) A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 98:502–506

    Article  PubMed  CAS  Google Scholar 

  9. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312

    Article  PubMed  CAS  Google Scholar 

  10. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA (2004) Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28:783–789

    Article  PubMed  CAS  Google Scholar 

  11. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O (2003) Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52:2546–2453

    Article  PubMed  Google Scholar 

  12. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG (2001) Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87:44–48

    Article  PubMed  CAS  Google Scholar 

  13. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27:2450–2457

    Article  PubMed  CAS  Google Scholar 

  14. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27:1680–1687

    Article  PubMed  CAS  Google Scholar 

  15. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T (2004) Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem 279:16154–16160

    Article  PubMed  CAS  Google Scholar 

  16. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK (2005) Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45:1649–1653

    Article  PubMed  CAS  Google Scholar 

  17. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Khang MH, Ahn TH, Choi IS, Shin EK (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687–3692

    Article  PubMed  CAS  Google Scholar 

  18. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK (2005) Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28:1419–1424

    Article  PubMed  CAS  Google Scholar 

  19. Wagner JA, Larson PJ, Weiss S, Miller JL, Doebber TW, Wu MS, Moller DE, Gottesdiener KM (2005) Individual and combined effects of peroxisome proliferators-activated receptor and gamma-agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol 45:504–513

    Article  PubMed  CAS  Google Scholar 

  20. Jové M, Planavila A, Cabrero A, Novell F, Ros E, Zambón D, Laguna JC, Carrera MV (2003) Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue. Metabolism 52:351–355

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department 2 — Grosshadern, University Hospital Munich, Marchioninistrasse 15, D-81377, Munich, Germany

    C. Otto, R. J. A. Frost & K. G. Parhofer

  2. Medical Department — Innenstadt, University Hospital Munich, Munich, Germany

    B. Otto

  3. Institute of Clinical Chemistry — Grosshadern, University Hospital Munich, Munich, Germany

    M. Vogeser

  4. Department of Clinical Nutrition, German Institute of Human Nutrition, Bergholz-Rehbrücke, Germany

    A. F. H. Pfeiffer & J. Spranger

  5. Department of Endocrinology, Diabetes and Nutrition Charité-University Medicine, Campus Benjamin Franklin, Berlin, Germany

    A. F. H. Pfeiffer & J. Spranger

Authors
  1. C. Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. J. A. Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Vogeser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. F. H. Pfeiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Spranger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. G. Parhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. G. Parhofer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Otto, C., Otto, B., Frost, R.J.A. et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 44, 65–68 (2007). https://doi.org/10.1007/s00592-007-0244-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-007-0244-8

Key words

Search

Navigation